

# Steven A Narod

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/381843/publications.pdf>

Version: 2024-02-01

466  
papers

49,381  
citations

3151

92  
h-index

1751

212  
g-index

468  
all docs

468  
docs citations

468  
times ranked

32562  
citing authors

#	ARTICLE	IF	CITATIONS
1	A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. <i>Science</i> , 1994, 266, 66-71.	6.0	5,747
2	Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence. <i>Clinical Cancer Research</i> , 2007, 13, 4429-4434.	3.2	3,807
3	Identification of the breast cancer susceptibility gene BRCA2. <i>Nature</i> , 1995, 378, 789-792.	13.7	3,230
4	Risks of cancer in BRCA1-mutation carriers. <i>Lancet</i> , The, 1994, 343, 692-695.	6.3	1,764
5	Prophylactic Oophorectomy in Carriers of BRCA1 or BRCA2 Mutations. <i>New England Journal of Medicine</i> , 2002, 346, 1616-1622.	13.9	1,565
6	Bilateral Prophylactic Mastectomy Reduces Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: The PROSE Study Group. <i>Journal of Clinical Oncology</i> , 2004, 22, 1055-1062.	0.8	1,095
7	Surveillance of BRCA1 and BRCA2 Mutation Carriers With Magnetic Resonance Imaging, Ultrasound, Mammography, and Clinical Breast Examination. <i>JAMA - Journal of the American Medical Association</i> , 2004, 292, 1317.	3.8	1,033
8	Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations. <i>Nature Genetics</i> , 2002, 31, 55-59.	9.4	1,001
9	Prevalence and Penetrance of Germline BRCA1 and BRCA2 Mutations in a Population Series of 649 Women with Ovarian Cancer. <i>American Journal of Human Genetics</i> , 2001, 68, 700-710.	2.6	918
10	Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. <i>Nature Reviews Cancer</i> , 2015, 15, 668-679.	12.8	839
11	BRCA1 and BRCA2: 1994 and beyond. <i>Nature Reviews Cancer</i> , 2004, 4, 665-676.	12.8	824
12	Contralateral Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. <i>Journal of Clinical Oncology</i> , 2004, 22, 2328-2335.	0.8	595
13	Population BRCA1 and BRCA2 Mutation Frequencies and Cancer Penetrances: A Kinship Cohort Study in Ontario, Canada. <i>Journal of the National Cancer Institute</i> , 2006, 98, 1694-1706.	3.0	571
14	Salpingo-oophorectomy and the Risk of Ovarian, Fallopian Tube, and Peritoneal Cancers in Women With a BRCA1 or BRCA2 Mutation. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 185.	3.8	544
15	Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. <i>Lancet</i> , The, 2000, 356, 1876-1881.	6.3	538
16	Impact of Oophorectomy on Cancer Incidence and Mortality in Women With a BRCA1 or BRCA2 Mutation. <i>Journal of Clinical Oncology</i> , 2014, 32, 1547-1553.	0.8	523
17	Pathologic Complete Response Rates in Young Women With BRCA1-Positive Breast Cancers After Neoadjuvant Chemotherapy. <i>Journal of Clinical Oncology</i> , 2010, 28, 375-379.	0.8	500
18	Differences in Breast Cancer Stage at Diagnosis and Cancer-Specific Survival by Race and Ethnicity in the United States. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 165.	3.8	489

#	ARTICLE	IF	CITATIONS
19	Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ. <i>JAMA Oncology</i> , 2015, 1, 888.	3.4	477
20	Pattern of metastatic spread in triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2009, 115, 423-428.	1.1	455
21	CHEK2 Is a Multiorgan Cancer Susceptibility Gene. <i>American Journal of Human Genetics</i> , 2004, 75, 1131-1135.	2.6	426
22	Improved survival in women withBRCA-associated ovarian carcinoma. <i>Cancer</i> , 2003, 97, 2187-2195.	2.0	419
23	Breast Cancer Risk Following Bilateral Oophorectomy in BRCA1 and BRCA2 Mutation Carriers: An International Case-Control Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 7491-7496.	0.8	408
24	Effect of Short-Term Hormone Replacement Therapy on Breast Cancer Risk Reduction After Bilateral Prophylactic Oophorectomy in BRCA1 and BRCA2 Mutation Carriers: The PROSE Study Group. <i>Journal of Clinical Oncology</i> , 2005, 23, 7804-7810.	0.8	396
25	Prevalence and Penetrance of BRCA1 and BRCA2 Gene Mutations in Unselected Ashkenazi Jewish Women With Breast Cancer. <i>Journal of the National Cancer Institute</i> , 1999, 91, 1241-1247.	3.0	363
26	Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. <i>Gynecologic Oncology</i> , 2006, 100, 58-64.	0.6	349
27	Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. <i>Gynecologic Oncology</i> , 2011, 121, 353-357.	0.6	342
28	Oral Contraceptives and the Risk of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. <i>Journal of the National Cancer Institute</i> , 2002, 94, 1773-1779.	3.0	318
29	Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. <i>Nature Genetics</i> , 1994, 8, 392-398.	9.4	313
30	International variation in rates of uptake of preventive options in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>International Journal of Cancer</i> , 2008, 122, 2017-2022.	2.3	306
31	Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2009, 115, 359-363.	1.1	299
32	Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. <i>Nature Medicine</i> , 1996, 2, 1179-1183.	15.2	294
33	BRCA1 and BRCA2 Mutation Analysis of 208 Ashkenazi Jewish Women with Ovarian Cancer. <i>American Journal of Human Genetics</i> , 2000, 66, 1259-1272.	2.6	294
34	Can advanced-stage ovarian cancer be cured?. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 255-261.	12.5	292
35	Estrogen Receptor Status in BRCA1- and BRCA2-Related Breast Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 2029-2034.	3.2	270
36	Clinical Outcomes of Breast Cancer in Carriers of <i>BRCA1</i> and <i>BRCA2</i> Mutations. <i>New England Journal of Medicine</i> , 2007, 357, 115-123.	13.9	268

#	ARTICLE	IF	CITATIONS
37	Prophylactic Surgery Decisions and Surveillance Practices One Year Following BRCA1/2 Testing. <i>Preventive Medicine</i> , 2000, 31, 75-80.	1.6	248
38	Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update. <i>International Journal of Cancer</i> , 2006, 118, 2281-2284.	2.3	246
39	Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. <i>PLoS Genetics</i> , 2013, 9, e1003212.	1.5	244
40	Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. <i>BMJ</i> , The, 2014, 348, g226-g226.	3.0	238
41	Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 401-405.	1.1	224
42	Founder Mutations in the BRCA1 Gene in Polish Families with Breast-Ovarian Cancer. <i>American Journal of Human Genetics</i> , 2000, 66, 1963-1968.	2.6	222
43	Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. <i>Lancet Oncology</i> , The, 2007, 8, 26-34.	5.1	220
44	Risk of Breast Cancer in Women With a <i>CHEK2</i> Mutation With and Without a Family History of Breast Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 3747-3752.	0.8	207
45	Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer: a population-based cohort study. <i>Lancet Oncology</i> , The, 2014, 15, 223-231.	5.1	203
46	Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. <i>British Journal of Cancer</i> , 2011, 104, 1384-1392.	2.9	195
47	A descriptive study of BRCA1 testing and reactions to disclosure of test results. , 1997, 79, 2219-2228.		192
48	An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast Cancer Linkage Consortium. <i>American Journal of Human Genetics</i> , 1995, 56, 254-64.	2.6	188
49	Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis. <i>BMJ</i> , The, 2016, 352, i851.	3.0	180
50	Hormone Therapy and the Risk of Breast Cancer in BRCA1 Mutation Carriers. <i>Journal of the National Cancer Institute</i> , 2008, 100, 1361-1367.	3.0	179
51	Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. <i>Breast Cancer Research</i> , 2012, 14, R110.	2.2	179
52	Breast-feeding and the Risk of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. <i>Journal of the National Cancer Institute</i> , 2004, 96, 1094-1098.	3.0	172
53	Screening for Founder Mutations in <i>BRCA1</i> and <i>BRCA2</i> in Unselected Jewish Women. <i>Journal of Clinical Oncology</i> , 2010, 28, 387-391.	0.8	172
54	Germline RECQL mutations are associated with breast cancer susceptibility. <i>Nature Genetics</i> , 2015, 47, 643-646.	9.4	168

#	ARTICLE	IF	CITATIONS
55	Bilateral Oophorectomy and Breast Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	160
56	Modifiers of risk of hereditary breast and ovarian cancer. <i>Nature Reviews Cancer</i> , 2002, 2, 113-123.	12.8	159
57	Breast cancer in young women. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 460-470.	12.5	159
58	The impact of family history on early detection of prostate cancer. <i>Nature Medicine</i> , 1995, 1, 99-101.	15.2	156
59	Effect of pregnancy as a risk factor for breast cancer in <i>BRCA1/BRCA2</i> mutation carriers. <i>International Journal of Cancer</i> , 2005, 117, 988-991.	2.3	152
60	<i>NBS1</i> Is a Prostate Cancer Susceptibility Gene. <i>Cancer Research</i> , 2004, 64, 1215-1219.	0.4	141
61	<i>BRCA</i> mutations in the management of breast cancer: the state of the art. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 702-707.	12.5	140
62	Congenital anomalies and childhood cancer in Great Britain. <i>American Journal of Human Genetics</i> , 1997, 60, 474-85.	2.6	138
63	Clinical outcomes in women with breast cancer and a <i>PALB2</i> mutation: a prospective cohort analysis. <i>Lancet Oncology</i> , The, 2015, 16, 638-644.	5.1	137
64	Response to neo-adjuvant chemotherapy in women with <i>BRCA1</i> -positive breast cancers. <i>Breast Cancer Research and Treatment</i> , 2008, 108, 289-296.	1.1	136
65	Low-grade serous ovarian cancer: A review. <i>Gynecologic Oncology</i> , 2016, 143, 433-438.	0.6	135
66	Rapid progression of prostate cancer in men with a <i>BRCA2</i> mutation. <i>British Journal of Cancer</i> , 2008, 99, 371-374.	2.9	132
67	Identification of a novel truncating <i>PALB2</i> mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women. <i>Breast Cancer Research</i> , 2007, 9, R83.	2.2	126
68	Hormone replacement therapy and the risk of breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 669-676.	12.5	126
69	Long-Term Ovarian Cancer Survival Associated With Mutation in <i>BRCA1</i> or <i>BRCA2</i> . <i>Journal of the National Cancer Institute</i> , 2013, 105, 141-148.	3.0	126
70	Survival and cardiovascular events in men treated with testosterone replacement therapy: an intention-to-treat observational cohort study. <i>Lancet Diabetes and Endocrinology</i> , the, 2016, 4, 498-506.	5.5	126
71	Gene-body hypermethylation of <i>ATM</i> in peripheral blood DNA of bilateral breast cancer patients. <i>Human Molecular Genetics</i> , 2009, 18, 1332-1342.	1.4	124
72	Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among <i>BRCA1</i> Mutation Carriers. <i>JAMA Oncology</i> , 2018, 4, 1059.	3.4	121

#	ARTICLE	IF	CITATIONS
73	Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study. <i>British Journal of Cancer</i> , 2014, 110, 530-534.	2.9	120
74	Effect of Smoking on Breast Cancer in Carriers of Mutant BRCA1 or BRCA2 Genes. <i>Journal of the National Cancer Institute</i> , 1998, 90, 761-765.	3.0	118
75	Why have breast cancer mortality rates declined?. <i>Journal of Cancer Policy</i> , 2015, 5, 8-17.	0.6	117
76	The relationship between tumour size, nodal status and distant metastases: on the origins of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 170, 647-656.	1.1	117
77	Is Uterine Papillary Serous Adenocarcinoma a Manifestation of the Hereditary Breast-Ovarian Cancer Syndrome?. <i>Gynecologic Oncology</i> , 2000, 79, 477-481.	0.6	113
78	Ten-Year Survival in Patients With BRCA1-Negative and BRCA1-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 3191-3196.	0.8	112
79	Psychosocial functioning in women who have undergone bilateral prophylactic mastectomy. <i>Psycho-Oncology</i> , 2004, 13, 14-25.	1.0	111
80	Breast cancer predisposing alleles in Poland. <i>Breast Cancer Research and Treatment</i> , 2005, 92, 19-24.	1.1	110
81	Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation. <i>Fertility and Sterility</i> , 2013, 99, 1724-1728.	0.5	110
82	Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. <i>JAMA Oncology</i> , 2015, 1, 306.	3.4	107
83	The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: An international prospective cohort study. <i>Gynecologic Oncology</i> , 2013, 130, 127-131.	0.6	106
84	Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. <i>Lancet Oncology</i> , The, 2006, 7, 402-406.	5.1	104
85	Diet, lifestyle and BRCA-related breast cancer risk among French-Canadians. <i>Breast Cancer Research and Treatment</i> , 2006, 98, 285-294.	1.1	104
86	Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2005, 7, R833-43.	2.2	103
87	Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation. <i>British Journal of Cancer</i> , 2009, 100, 421-425.	2.9	103
88	Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 150, 71-80.	1.1	103
89	Modifiers of risk of hereditary breast cancer. <i>Oncogene</i> , 2006, 25, 5832-5836.	2.6	102
90	A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in Poland. <i>Breast Cancer Research and Treatment</i> , 2007, 102, 119-122.	1.1	102

#	ARTICLE	IF	CITATIONS
91	Changes in Psychosocial Functioning 1 Year After Mastectomy Alone, Delayed Breast Reconstruction, or Immediate Breast Reconstruction. <i>Annals of Surgical Oncology</i> , 2012, 19, 233-241.	0.7	101
92	International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation. <i>British Journal of Cancer</i> , 2019, 121, 15-21.	2.9	101
93	Family history of cancer is a risk factor for squamous cell carcinoma of the head and neck in Brazil: A case-control study. <i>International Journal of Cancer</i> , 1995, 63, 769-773.	2.3	98
94	CHEK2 mutations and the risk of papillary thyroid cancer. <i>International Journal of Cancer</i> , 2015, 137, 548-552.	2.3	97
95	The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 134, 462-467.	0.6	93
96	Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status. <i>Gynecologic Oncology</i> , 2016, 140, 42-47.	0.6	93
97	An evaluation of needs of female BRCA1 and BRCA2 carriers undergoing genetic counselling. <i>Journal of Medical Genetics</i> , 2000, 37, 866-874.	1.5	92
98	Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2012, 14, R42.	2.2	92
99	Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers. <i>Breast Cancer Research and Treatment</i> , 2009, 118, 131-137.	1.1	89
100	Family History of Cancer and Cancer Risks in Women with BRCA1 or BRCA2 Mutations. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1874-1878.	3.0	89
101	An inherited NBN mutation is associated with poor prognosis prostate cancer. <i>British Journal of Cancer</i> , 2013, 108, 461-468.	2.9	89
102	Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case-control study. <i>Cancer Causes and Control</i> , 2008, 19, 1111-1119.	0.8	87
103	Hereditary ovarian cancer in Poland. <i>International Journal of Cancer</i> , 2003, 106, 942-945.	2.3	82
104	Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland. <i>Breast Cancer Research and Treatment</i> , 2006, 95, 105-109.	1.1	82
105	Association of the Timing of Pregnancy With Survival in Women With Breast Cancer. <i>JAMA Oncology</i> , 2017, 3, 659.	3.4	82
106	Mammographic density and the risk of breast cancer recurrence after breast-conserving surgery. <i>Cancer</i> , 2009, 115, 5780-5787.	2.0	81
107	Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. <i>European Journal of Cancer</i> , 2021, 146, 30-47.	1.3	81
108	Long-term follow-up of Jewish women with a BRCA1 and BRCA2 mutation who underwent population genetic screening. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 735-740.	1.1	79

#	ARTICLE	IF	CITATIONS
109	Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: A systematic review. <i>Cancer Treatment Reviews</i> , 2012, 38, 318-328.	3.4	77
110	Why have ovarian cancer mortality rates declined? Part I. Incidence. <i>Gynecologic Oncology</i> , 2015, 138, 741-749.	0.6	77
111	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv315.	3.0	77
112	BRCA Carriers, Prophylactic Salpingo-Oophorectomy and Menopause: Clinical Management Considerations and Recommendations. <i>Women's Health</i> , 2012, 8, 543-555.	0.7	75
113	Breast Cancer Risk Perception Among Women Who Have Undergone Prophylactic Bilateral Mastectomy. <i>Journal of the National Cancer Institute</i> , 2002, 94, 1564-1569.	3.0	73
114	The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation. <i>Familial Cancer</i> , 2005, 4, 97-103.	0.9	73
115	Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2011, 127, 287-296.	1.1	73
116	BRCA1 and BRCA2 mutations and the risk for colorectal cancer. <i>Clinical Genetics</i> , 2015, 87, 411-418.	1.0	73
117	Brca2 hereditary breast cancer pathophenotype. <i>Breast Cancer Research and Treatment</i> , 1997, 44, 275-277.	1.1	71
118	Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. <i>Cancer Causes and Control</i> , 2005, 16, 667-674.	0.8	71
119	Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil. <i>Breast Cancer Research and Treatment</i> , 2007, 103, 349-353.	1.1	71
120	The impact of prophylactic salpingo-oophorectomy on quality of life and psychological distress in women with a BRCA mutation. <i>Psycho-Oncology</i> , 2013, 22, 212-219.	1.0	71
121	Current understanding of the epidemiology and clinical implications of BRCA1 and BRCA2 mutations for ovarian cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2002, 14, 19-26.	0.9	68
122	Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2014, 143, 579-586.	1.1	68
123	Quality of life and health status after prophylactic salpingo-oophorectomy in women who carry a BRCA mutation: A review. <i>Maturitas</i> , 2011, 70, 261-265.	1.0	67
124	Impact of microinvasion on breast cancer mortality in women with ductal carcinoma in situ. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 787-795.	1.1	66
125	Androgens and breast cancer. <i>Steroids</i> , 2012, 77, 1-9.	0.8	65
126	Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation. <i>Gynecologic Oncology</i> , 2018, 150, 85-91.	0.6	65



#	ARTICLE	IF	CITATIONS
127	A high prevalence of BRCA1 mutations among breast cancer patients from the Bahamas. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 591-596.	1.1	63
128	Diabetes and breast cancer among women with <i>BRCA1</i> and <i>BRCA2</i> mutations. <i>Cancer</i> , 2011, 117, 1812-1818.	2.0	62
129	Germline CHEK2 mutations and colorectal cancer risk: different effects of a missense and truncating mutations?. <i>European Journal of Human Genetics</i> , 2007, 15, 237-241.	1.4	61
130	The prevalence of BRCA1 and BRCA2 mutations among young Mexican women with triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 150, 389-394.	1.1	61
131	A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer families. <i>Human Mutation</i> , 2002, 20, 352-357.	1.1	60
132	The impact of a BRCA2 mutation on mortality from screen-detected prostate cancer. <i>British Journal of Cancer</i> , 2014, 111, 1238-1240.	2.9	60
133	Fusion in the ETS gene family and prostate cancer. <i>British Journal of Cancer</i> , 2008, 99, 847-851.	2.9	57
134	Tumour Size Predicts Long-Term Survival among Women with Lymph Node-Positive Breast Cancer. <i>Current Oncology</i> , 2012, 19, 249-253.	0.9	57
135	The impact of pregnancy on breast cancer survival in women who carry a BRCA1 or BRCA2 mutation. <i>Breast Cancer Research and Treatment</i> , 2013, 142, 177-185.	1.1	57
136	Mutations in Fanconi anemia genes and the risk of esophageal cancer. <i>Human Genetics</i> , 2011, 129, 573-582.	1.8	56
137	Factors influencing ovulation and the risk of ovarian cancer in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>International Journal of Cancer</i> , 2015, 137, 1136-1146.	2.3	56
138	Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family history. <i>Clinical Genetics</i> , 1999, 55, 318-324.	1.0	55
139	Multiple primary cancers as a guide to heritability. <i>International Journal of Cancer</i> , 2014, 135, 1756-1763.	2.3	55
140	Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case-control study. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 365-373.	1.1	55
141	Epidemiologic factors that predict long-term survival following a diagnosis of epithelial ovarian cancer. <i>British Journal of Cancer</i> , 2017, 116, 964-971.	2.9	55
142	Survival of patients with BRCA1-associated breast cancer diagnosed in an MRI-based surveillance program. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 155-161.	1.1	54
143	Bilateral breast cancers. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 157-166.	12.5	54
144	Estrogen receptor status in CHEK2-positive breast cancers: implications for chemoprevention. <i>Clinical Genetics</i> , 2009, 75, 72-78.	1.0	53

#	ARTICLE	IF	CITATIONS
145	The spectrum of <i>BRCA1</i> and <i>BRCA2</i> mutations in breast cancer patients in the Bahamas. <i>Clinical Genetics</i> , 2014, 85, 64-67.	1.0	53
146	Hormonal Prevention of Hereditary Breast Cancer. <i>Annals of the New York Academy of Sciences</i> , 2001, 952, 36-43.	1.8	52
147	Polymorphisms in folate metabolizing enzymes and transport proteins and the risk of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2008, 112, 585-593.	1.1	51
148	Testing for <i>CHEK2</i> in the cancer genetics clinic: ready for prime time?. <i>Clinical Genetics</i> , 2010, 78, 1-7.	1.0	51
149	Time to disease recurrence in basal-type breast cancers. <i>Cancer</i> , 2009, 115, 4917-4923.	2.0	50
150	Prevalence of <i>BRCA1</i> and <i>BRCA2</i> mutations in unselected breast cancer patients from Peru. <i>Clinical Genetics</i> , 2015, 88, 371-375.	1.0	50
151	Patient satisfaction and cancer-related distress among unselected Jewish women undergoing genetic testing for <i>BRCA1</i> and <i>BRCA2</i> . <i>Clinical Genetics</i> , 2010, 78, 411-417.	1.0	49
152	The incidence of bone metastasis after early-stage breast cancer in Canada. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 587-595.	1.1	49
153	Is invasion a necessary step for metastases in breast cancer?. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 9-23.	1.1	49
154	Family history as a predictor of uptake of cancer preventive procedures by women with a <i>BRCA1</i> or <i>BRCA2</i> mutation. <i>Clinical Genetics</i> , 2008, 73, 474-479.	1.0	48
155	The expected benefit of preventive mastectomy on breast cancer incidence and mortality in <i>BRCA</i> mutation carriers, by age at mastectomy. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 263-267.	1.1	48
156	<i>BRCA1</i> and <i>BRCA2</i> hereditary breast carcinoma phenotypes. <i>Cancer</i> , 1997, 80, 543-556.	2.0	47
157	Smoking and the risk of breast cancer among carriers of <i>BRCA</i> mutations. <i>International Journal of Cancer</i> , 2004, 110, 413-416.	2.3	47
158	Oophorectomy after Menopause and the Risk of Breast Cancer in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1089-1096.	1.1	47
159	Fallopian Tube Lesions in Women at High Risk for Ovarian Cancer: A Multicenter Study. <i>Cancer Prevention Research</i> , 2018, 11, 697-706.	0.7	47
160	The risk of gastric cancer in carriers of <i>CHEK2</i> mutations. <i>Familial Cancer</i> , 2013, 12, 473-478.	0.9	46
161	A Low Selenium Level Is Associated with Lung and Laryngeal Cancers. <i>PLoS ONE</i> , 2013, 8, e59051.	1.1	46
162	Age at first birth and the risk of breast cancer in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2007, 105, 221-228.	1.1	45

#	ARTICLE	IF	CITATIONS
163	Why have ovarian cancer mortality rates declined? Part II. Case-fatality. <i>Gynecologic Oncology</i> , 2015, 138, 750-756.	0.6	45
164	A Comparison of Bilateral Breast Cancers in BRCA Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 1534-1538.	1.1	44
165	CDKN2A mutation in a non-FAMMM kindred with cancers at multiple sites results in a functionally abnormal protein. , 1997, 73, 531-536.		43
166	Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. <i>Gynecologic Oncology</i> , 2006, 100, 83-88.	0.6	43
167	Performance analysis of a machine learning flagging system used to identify a group of individuals at a high risk for colorectal cancer. <i>PLoS ONE</i> , 2017, 12, e0171759.	1.1	43
168	Genetic risk assessment and prevention: the role of genetic testing panels in breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1315-1326.	1.1	42
169	Chromosomal Instability in Cell-Free DNA Is a Serum Biomarker for Prostate Cancer. <i>Clinical Chemistry</i> , 2015, 61, 239-248.	1.5	41
170	BRCA1-positive breast cancers in young women from Poland. <i>Breast Cancer Research and Treatment</i> , 2006, 99, 71-76.	1.1	40
171	The contribution of founder mutations to early-onset breast cancer in French-Canadian women. <i>Clinical Genetics</i> , 2009, 76, 421-426.	1.0	40
172	The role of body size and physical activity on the risk of breast cancer in BRCA mutation carriers. <i>Cancer Causes and Control</i> , 2015, 26, 333-344.	0.8	40
173	Effects of bilateral salpingo-oophorectomy on menopausal symptoms and sexual functioning among women with a BRCA1 or BRCA2 mutation. <i>Gynecologic Oncology</i> , 2019, 152, 145-150.	0.6	40
174	Genetic testing for <i>RAD51C</i> mutations: in the clinic and community. <i>Clinical Genetics</i> , 2015, 88, 303-312.	1.0	39
175	The spectrum of mutations predisposing to familial breast cancer in Poland. <i>International Journal of Cancer</i> , 2019, 145, 3311-3320.	2.3	39
176	The risk of breast cancer in women with a BRCA1 mutation from North America and Poland. <i>International Journal of Cancer</i> , 2012, 131, 229-234.	2.3	38
177	Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. <i>Fertility and Sterility</i> , 2016, 105, 781-785.	0.5	38
178	The relationship between local recurrence and death in early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 175-185.	1.1	38
179	Complications following surgery with or without radiotherapy or radiotherapy alone for prostate cancer. <i>British Journal of Cancer</i> , 2015, 112, 977-982.	2.9	37
180	Which Genes for Hereditary Breast Cancer?. <i>New England Journal of Medicine</i> , 2021, 384, 471-473.	13.9	37

#	ARTICLE	IF	CITATIONS
181	Mutations of the MYH gene do not substantially contribute to the risk of breast cancer. Breast Cancer Research and Treatment, 2009, 114, 575-578.	1.1	36
182	Serum selenium levels predict survival after breast cancer. Breast Cancer Research and Treatment, 2018, 167, 591-598.	1.1	36
183	Personalised medicine and population health: breast and ovarian cancer. Human Genetics, 2018, 137, 769-778.	1.8	36
184	Factors Associated with Breast Cancer Mortality after Local Recurrence. Current Oncology, 2014, 21, 418-425.	0.9	35
185	Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2014, 146, 421-427.	1.1	35
186	Recurrent mutations of <scp>BRCA1</scp> and <scp>BRCA2</scp> in Poland: an update. Clinical Genetics, 2015, 87, 288-292.	1.0	35
187	Thyroid hormone receptor $\hat{\pm}$ in breast cancer: prognostic and therapeutic implications. Breast Cancer Research and Treatment, 2015, 149, 293-301.	1.1	35
188	Oestrogen receptor status, treatment and breast cancer prognosis in Icelandic BRCA2 mutation carriers. British Journal of Cancer, 2016, 115, 776-783.	2.9	35
189	Association Between Use of Antithrombotic Medication and Hematuria-Related Complications. JAMA - Journal of the American Medical Association, 2017, 318, 1260.	3.8	35
190	A comparison of the detection of BRCA mutation carriers through the provision of Jewish population-based genetic testing compared with clinic-based genetic testing. British Journal of Cancer, 2013, 109, 777-779.	2.9	34
191	Methylation of the BRCA1 promoter in peripheral blood DNA is associated with triple-negative and medullary breast cancer. Breast Cancer Research and Treatment, 2014, 148, 615-622.	1.1	34
192	Complications After Radical Prostatectomy or Radiotherapy for Prostate Cancer: Results of a Population-based, Propensity Score-matched Analysis. Urology, 2015, 85, 621-628.	0.5	34
193	A prospective study of mastectomy patients with and without delayed breast reconstruction: Long-term psychosocial functioning in the breast cancer survivorship period. Journal of Surgical Oncology, 2015, 111, 258-264.	0.8	34
194	Mutations predisposing to breast cancer in 12 candidate genes in breast cancer patients from Poland. Clinical Genetics, 2015, 88, 366-370.	1.0	34
195	Functionally Null <i>RAD51D</i> Missense Mutation Associates Strongly with Ovarian Carcinoma. Cancer Research, 2017, 77, 4517-4529.	0.4	34
196	Early radiation exposures and BRCA1-associated breast cancer in young women from Poland. Breast Cancer Research and Treatment, 2008, 112, 581-584.	1.1	33
197	BRCA1 mutations and prostate cancer in Poland. European Journal of Cancer Prevention, 2008, 17, 62-66.	0.6	33
198	BRCA1 mutations and colorectal cancer in Poland. Familial Cancer, 2010, 9, 541-544.	0.9	33

#	ARTICLE	IF	CITATIONS
199	Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?. <i>Gynecologic Oncology</i> , 2017, 145, 346-351.	0.6	33
200	<i>BRCA1</i> promoter methylation in peripheral blood is associated with the risk of triple-negative breast cancer. <i>International Journal of Cancer</i> , 2020, 146, 1293-1298.	2.3	33
201	The joint effect of smoking and AIB1 on breast cancer risk in <i>BRCA1</i> mutation carriers. <i>Carcinogenesis</i> , 2006, 27, 599-605.	1.3	32
202	CHEK2-Positive Breast Cancers in Young Polish Women. <i>Clinical Cancer Research</i> , 2006, 12, 4832-4835.	3.2	32
203	Prevalence of <i>BRCA1</i> and <i>BRCA2</i> mutations in breast cancer patients from Cuba. <i>Familial Cancer</i> , 2008, 7, 275-279.	0.9	32
204	The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30. <i>Familial Cancer</i> , 2009, 8, 563-567.	0.9	32
205	Modes of delivery of genetic testing services and the uptake of cancer risk management strategies in <i>BRCA1</i> and <i>BRCA2</i> carriers. <i>Clinical Genetics</i> , 2014, 85, 49-53.	1.0	32
206	Identification and Validation of a Five MicroRNA Signature Predictive of Prostate Cancer Recurrence and Metastasis: A Cohort Study. <i>Journal of Cancer</i> , 2015, 6, 1160-1171.	1.2	32
207	Why have ovarian cancer mortality rates declined? Part III. Prospects for the future. <i>Gynecologic Oncology</i> , 2015, 138, 757-761.	0.6	32
208	The prognostic effect of estrogen receptor status differs for younger versus older breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 391-402.	1.1	32
209	Direct-to-patient <i>BRCA1</i> testing: the Twoj Styl experience. <i>Breast Cancer Research and Treatment</i> , 2006, 100, 239-245.	1.1	31
210	<i>BRCA1</i> and <i>BRCA2</i> families and the risk of skin cancer. <i>Familial Cancer</i> , 2010, 9, 489-493.	0.9	31
211	The G84E mutation in the <i>HOXB13</i> gene is associated with an increased risk of prostate cancer in Poland. <i>Prostate</i> , 2013, 73, 542-548.	1.2	31
212	Should all <i>BRCA1</i> mutation carriers with stage I breast cancer receive chemotherapy?. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 273-279.	1.1	31
213	Preferences for breast cancer risk reduction among <i>BRCA1/BRCA2</i> mutation carriers: a discrete-choice experiment. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 433-444.	1.1	31
214	Age of diagnosis, tumor size, and survival after breast cancer: implications for mammographic screening. <i>Breast Cancer Research and Treatment</i> , 2011, 128, 259-266.	1.1	30
215	The impact of contralateral mastectomy on mortality in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 128, 581-583.	1.1	29
216	Recurrent <i>BRCA1</i> and <i>BRCA2</i> Mutations in Mexican Women with Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 498-505.	1.1	29

#	ARTICLE	IF	CITATIONS
217	Revisiting breast cancer patients who previously tested negative for BRCA mutations using a 12-gene panel. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 135-142.	1.1	29
218	A Comprehensive Analysis of MNG1, TCO1, fPTC, PTEN, TSHR, and TRKA in Familial Nonmedullary Thyroid Cancer: Confirmation of Linkage to TCO1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 3701-3704.	1.8	29
219	The contribution of founder mutations in <i>BRCA1</i> to breast and ovarian cancer in Lithuania. <i>Clinical Genetics</i> , 2010, 78, 373-376.	1.0	28
220	Disappearing Breast Cancers. <i>Current Oncology</i> , 2012, 19, 59-60.	0.9	28
221	International Rates of Breast Reconstruction After Prophylactic Mastectomy in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Annals of Surgical Oncology</i> , 2013, 20, 3817-3822.	0.7	28
222	Risk factors for endometrial cancer among women with a <i>BRCA1</i> or <i>BRCA2</i> mutation: a case control study. <i>Familial Cancer</i> , 2015, 14, 383-391.	0.9	28
223	Blood cadmium levels as a marker for early lung cancer detection. <i>Journal of Trace Elements in Medicine and Biology</i> , 2021, 64, 126682.	1.5	28
224	Plasma osteoprotegerin and breast cancer risk in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>Oncotarget</i> , 2016, 7, 86687-86694.	0.8	28
225	Smoking and the risk of breast cancer in <i>BRCA1</i> and <i>BRCA2</i> carriers: an update. <i>Breast Cancer Research and Treatment</i> , 2009, 114, 127-135.	1.1	27
226	Risk factors for carcinoma of the fallopian tube in women with and without a germline <i>BRCA</i> mutation. <i>Gynecologic Oncology</i> , 2010, 118, 155-159.	0.6	27
227	The R337H mutation in TP53 and breast cancer in Brazil. <i>Hereditary Cancer in Clinical Practice</i> , 2012, 10, 3.	0.6	27
228	Can we prevent <i>BRCA1</i> -associated breast cancer by RANKL inhibition?. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 11-16.	1.1	27
229	Mutations in ATM, NBN and <i>BRCA2</i> predispose to aggressive prostate cancer in Poland. <i>International Journal of Cancer</i> , 2020, 147, 2793-2800.	2.3	27
230	Bilateral Mastectomy in Women With Unilateral Breast Cancer. <i>JAMA Surgery</i> , 2021, 156, 569.	2.2	27
231	The risk of contralateral breast cancer: a SEER-based analysis. <i>British Journal of Cancer</i> , 2021, 125, 601-610.	2.9	27
232	Analysis of Platelet Count and New Cancer Diagnosis Over a 10-Year Period. <i>JAMA Network Open</i> , 2022, 5, e2141633.	2.8	27
233	Risk factors for non-invasive lesions of the fallopian tube in <i>BRCA</i> mutation carriers. <i>Gynecologic Oncology</i> , 2010, 118, 295-298.	0.6	26
234	<i>BRCA1</i> and <i>BRCA2</i> mutations among familial breast cancer patients from Costa Rica. <i>Clinical Genetics</i> , 2012, 82, 484-488.	1.0	26

#	ARTICLE	IF	CITATIONS
235	Plasma micronutrients, trace elements, and breast cancer in BRCA1 mutation carriers: an exploratory study. <i>Cancer Causes and Control</i> , 2012, 23, 1065-1074.	0.8	26
236	PPM1D Mutations in Circulating White Blood Cells and the Risk for Ovarian Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, djt323.	3.0	26
237	Predictors of time to death after distant recurrence in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 465-474.	1.1	26
238	Multiple therapeutic and preventive effects of 3,39-diindolylmethane on cancers including prostate cancer and high grade prostatic intraepithelial neoplasia. <i>Journal of Biomedical Research</i> , 2014, 28, 339-48.	0.7	25
239	Physical activity during adolescence and young adulthood and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 561-571.	1.1	25
240	Serum selenium levels and the risk of progression of laryngeal cancer. <i>PLoS ONE</i> , 2018, 13, e0184873.	1.1	25
241	Oestrogen receptor status and survival in women with BRCA2-associated breast cancer. <i>British Journal of Cancer</i> , 2019, 120, 398-403.	2.9	25
242	BARD1 is a Low/Moderate Breast Cancer Risk Gene: Evidence Based on an Association Study of the Central European p.Q564X Recurrent Mutation. <i>Cancers</i> , 2019, 11, 740.	1.7	25
243	Genetics of breast and ovarian cancer. <i>British Medical Bulletin</i> , 1994, 50, 656-676.	2.7	24
244	A common nonsense mutation of the BLM gene and prostate cancer risk and survival. <i>Gene</i> , 2013, 532, 173-176.	1.0	24
245	Mammography screening and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a prospective study. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 113-118.	1.1	24
246	Cardiovascular and Skeletal-related Events Following Localized Prostate Cancer Treatment: Role of Surgery, Radiotherapy, and Androgen Deprivation. <i>Urology</i> , 2016, 97, 145-152.	0.5	24
247	Time to death in breast cancer patients as an indicator of treatment response. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 659-669.	1.1	24
248	A Matched Case-Control Study of Risk Factors for Breast Cancer Risk in Vietnam. <i>International Journal of Breast Cancer</i> , 2016, 2016, 1-7.	0.6	23
249	Germline RECQL mutations in high risk Chinese breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 211-215.	1.1	23
250	Plasma folate, vitamin B-6, and vitamin B-12 and breast cancer risk in BRCA1- and BRCA2-mutation carriers: a prospective study. <i>American Journal of Clinical Nutrition</i> , 2016, 104, 671-677.	2.2	23
251	The contribution of founder mutations in <i>BRCA1</i> to breast cancer in Belarus. <i>Clinical Genetics</i> , 2010, 78, 377-380.	1.0	22
252	Prevalence of founder mutations in the <i>BRCA1</i> and <i>BRCA2</i> genes among unaffected women from the Bahamas. <i>Clinical Genetics</i> , 2016, 89, 328-331.	1.0	22

#	ARTICLE	IF	CITATIONS
253	Epistatic Relationship between the Cancer Susceptibility Genes CHEK2 and p27. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 572-576.	1.1	21
254	Telomere Length and Mortality Following a Diagnosis of Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2603-2606.	1.1	21
255	Frequency of germline PALB2 mutations among women with epithelial ovarian cancer. <i>Familial Cancer</i> , 2017, 16, 29-34.	0.9	21
256	BRCA1 mRNA levels following a 4-week intervention with oral 3,3'-diindolylmethane. <i>British Journal of Cancer</i> , 2014, 111, 1269-1274.	2.9	20
257	Strategies for recruitment of relatives of BRCA mutation carriers to a genetic testing program in the Bahamas. <i>Clinical Genetics</i> , 2015, 88, 182-186.	1.0	20
258	Germline TP53 mutational spectrum in French Canadians with breast cancer. <i>BMC Medical Genetics</i> , 2015, 16, 24.	2.1	20
259	Predictors of survival for breast cancer patients with a BRCA1 mutation. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 513-521.	1.1	20
260	The association between smoking and cancer incidence in BRCA1 and BRCA2 mutation carriers. <i>International Journal of Cancer</i> , 2018, 142, 2263-2272.	2.3	20
261	Predictors of long-term cancer-related distress among female BRCA1 and BRCA2 mutation carriers without a cancer diagnosis: an international analysis. <i>British Journal of Cancer</i> , 2020, 123, 268-274.	2.9	20
262	Androgen receptor and familial prostate cancer. <i>Nature Medicine</i> , 1995, 1, 848-849.	15.2	19
263	Tumour diploidy and survival in breast cancer patients with BRCA2 mutations. <i>Breast Cancer Research and Treatment</i> , 2013, 140, 375-384.	1.1	19
264	Health care provider recommendations for reducing cancer risks among women with a BRCA1 or BRCA2 mutation. <i>Clinical Genetics</i> , 2014, 85, 21-30.	1.0	19
265	Gene Sequencing for Pathogenic Variants Among Adults With Breast and Ovarian Cancer in the Caribbean. <i>JAMA Network Open</i> , 2021, 4, e210307.	2.8	19
266	CYP1B1 and predisposition to breast cancer in Poland. <i>Breast Cancer Research and Treatment</i> , 2007, 106, 383-388.	1.1	18
267	Genetic testing for BRCA1 and BRCA2 in the Province of Ontario. <i>Clinical Genetics</i> , 2016, 89, 304-311.	1.0	18
268	Correlation between germline mutations in MMR genes and microsatellite instability in ovarian cancer specimens. <i>Familial Cancer</i> , 2017, 16, 351-355.	0.9	18
269	The impact of nodal micrometastasis on mortality among women with early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 103-115.	1.1	18
270	Changes in Bone Mineral Density After Prophylactic Bilateral Salpingo-Oophorectomy in Carriers of a BRCA Mutation. <i>JAMA Network Open</i> , 2019, 2, e198420.	2.8	18



#	ARTICLE	IF	CITATIONS
271	Blood arsenic levels and the risk of familial breast cancer in Poland. <i>International Journal of Cancer</i> , 2020, 146, 2721-2727.	2.3	18
272	PALB2 mutations and prostate cancer risk and survival. <i>British Journal of Cancer</i> , 2021, 125, 569-575.	2.9	18
273	Excess of congenital abnormalities in French-Canadian children with neuroblastoma: A case series study from Montreal. , 1997, 29, 272-279.		17
274	Germline RAP80 mutations and susceptibility to breast cancer. <i>Breast Cancer Research and Treatment</i> , 2009, 113, 377-381.	1.1	17
275	Preventing ovarian cancer through genetic testing: a population-based study. <i>Clinical Genetics</i> , 2014, 86, 496-499.	1.0	17
276	Predicting the presence of colon cancer in members of a health maintenance organisation by evaluating analytes from standard laboratory records. <i>British Journal of Cancer</i> , 2017, 116, 944-950.	2.9	17
277	A Population-Based Cross-Sectional Study Comparing Breast Cancer Stage at Diagnosis between Immigrant and Canadian-Born Women in Ontario. <i>Breast Journal</i> , 2017, 23, 525-536.	0.4	17
278	Screening with magnetic resonance imaging, mammography and ultrasound in women at average and intermediate risk of breast cancer. <i>Hereditary Cancer in Clinical Practice</i> , 2017, 15, 4.	0.6	17
279	Prediction of findings at screening colonoscopy using a machine learning algorithm based on complete blood counts (ColonFlag). <i>PLoS ONE</i> , 2018, 13, e0207848.	1.1	17
280	Folic acid supplement use and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a case-control study. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 741-748.	1.1	17
281	Survival Differences in Chinese Versus White Women With Breast Cancer in the United States: A SEER-Based Analysis. <i>JCO Global Oncology</i> , 2020, 6, 1582-1592.	0.8	17
282	Prophylactic salpingectomy for the prevention of ovarian cancer: Who should we target?. <i>International Journal of Cancer</i> , 2020, 147, 1245-1251.	2.3	17
283	Variation in rates of uptake of preventive options by Canadian women carrying the BRCA1 or BRCA2 genetic mutation. <i>Open Medicine</i> , 2007, 1, e92-8.	1.5	17
284	Platelet Count and Survival after Cancer. <i>Cancers</i> , 2022, 14, 549.	1.7	17
285	Parental origin of mutation and the risk of breast cancer in a prospective study of women with a <i>BRCA1</i> or <i>BRCA2</i> mutation. <i>Clinical Genetics</i> , 2013, 84, 43-46.	1.0	16
286	Rates of risk-reducing surgery in Israeli <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>Clinical Genetics</i> , 2014, 85, 68-71.	1.0	16
287	New Rates of Interventions to Manage Complications of Modern Prostate Cancer Treatment in Older Men. <i>European Urology</i> , 2016, 69, 933-941.	0.9	16
288	Genetics of endometrial cancer. <i>Familial Cancer</i> , 2014, 13, 499-505.	0.9	15

#	ARTICLE	IF	CITATIONS
289	Exome Sequencing in BRCA1- and BRCA2-Negative Greek Families Identifies MDM1 and NBEAL1 as Candidate Risk Genes for Hereditary Breast Cancer. <i>Frontiers in Genetics</i> , 2019, 10, 1005.	1.1	15
290	A comparison of ovarian cancer mortality in women with BRCA1 mutations undergoing annual ultrasound screening or preventive oophorectomy. <i>Gynecologic Oncology</i> , 2019, 155, 270-274.	0.6	15
291	Genetic heterogeneity of early-onset familial breast cancer. <i>Human Genetics</i> , 1992, 89, 381-3.	1.8	14
292	Does family history predict the age at onset of new breast cancers in BRCA1 and BRCA2 mutation-positive families?. <i>Clinical Genetics</i> , 2010, 77, 273-279.	1.0	14
293	A Model for Breast Cancer Risk Based on Stem-Cell Theory. <i>Current Oncology</i> , 2012, 19, 9-11.	0.9	14
294	Age-specific incidence rates for breast cancer in carriers of BRCA1 mutations from Norway. <i>Clinical Genetics</i> , 2013, 83, 88-91.	1.0	14
295	Estimating survival rates after ovarian cancer among women tested for BRCA1 and BRCA2 mutations. <i>Clinical Genetics</i> , 2013, 83, 232-237.	1.0	14
296	Risk Factors for Premenopausal Breast Cancer in Bangladesh. <i>International Journal of Breast Cancer</i> , 2015, 2015, 1-7.	0.6	14
297	Should we screen for ovarian cancer? A commentary on the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) randomized trial. <i>Gynecologic Oncology</i> , 2016, 141, 191-194.	0.6	14
298	Thyroid hormone receptor beta-1 expression in early breast cancer: a validation study. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 709-717.	1.1	14
299	Serum Selenium Level Predicts 10-Year Survival after Breast Cancer. <i>Nutrients</i> , 2021, 13, 953.	1.7	14
300	The risk of breast cancer in BRCA1 and BRCA2 mutation carriers without a first-degree relative with breast cancer. <i>Clinical Genetics</i> , 2018, 93, 1063-1068.	1.0	14
301	Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers. <i>Gynecologic Oncology</i> , 2009, 115, 135-137.	0.6	13
302	Screening of women at high risk for breast cancer. <i>Preventive Medicine</i> , 2011, 53, 127-130.	1.6	13
303	BRCA1 Haploinsufficiency: Consequences for Breast Cancer. <i>Women's Health</i> , 2012, 8, 127-129.	0.7	13
304	Tumour characteristics among women with very low-risk breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 1241-1246.	1.1	13
305	The impact of oophorectomy on survival after breast cancer in BRCA1-positive breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 371-378.	1.1	13
306	Uninterrupted Sedentary Behavior Downregulates BRCA1 Gene Expression. <i>Cancer Prevention Research</i> , 2016, 9, 83-88.	0.7	13

#	ARTICLE	IF	CITATIONS
307	Computer-Assisted Flagging of Individuals at High Risk of Colorectal Cancer in a Large Health Maintenance Organization Using the ColonFlag Test. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-8.	1.0	13
308	Inherited variants in XRCC2 and the risk of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 657-663.	1.1	13
309	Recurrent Mutations in BRCA1, BRCA2, RAD51C, PALB2 and CHEK2 in Polish Patients with Ovarian Cancer. <i>Cancers</i> , 2021, 13, 849.	1.7	13
310	Incidence of Cancer Among Adults With Thrombocytosis in Ontario, Canada. <i>JAMA Network Open</i> , 2021, 4, e2120633.	2.8	13
311	The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers. <i>Canadian Urological Association Journal</i> , 2011, 5, e31-e35.	0.3	13
312	A survey of preventive measures among BRCA1 mutation carriers from Poland. <i>Clinical Genetics</i> , 2007, 71, 153-157.	1.0	12
313	Survival from breast cancer in patients with CHEK2 mutations. <i>Breast Cancer Research and Treatment</i> , 2014, 144, 397-403.	1.1	12
314	Screening for <scp>BRCA1</scp> and <scp>BRCA2</scp> mutations among French-Canadian breast cancer cases attending an outpatient clinic in Montreal. <i>Clinical Genetics</i> , 2014, 85, 31-35.	1.0	12
315	Prospective evaluation of alcohol consumption and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2015, 151, 435-441.	1.1	12
316	A model for estimating ovarian cancer risk: Application for preventive oophorectomy. <i>Gynecologic Oncology</i> , 2015, 139, 242-247.	0.6	12
317	Frequency of BRCA1 and BRCA2 causative founder variants in ovarian cancer patients in South-East Poland. <i>Hereditary Cancer in Clinical Practice</i> , 2018, 16, 6.	0.6	12
318	The effect of selection and referral biases for the treatment of localised prostate cancer with surgery or radiation. <i>British Journal of Cancer</i> , 2018, 118, 1399-1405.	2.9	12
319	Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 443-449.	1.1	12
320	Survival from breast cancer in women with a BRCA2 mutation by treatment. <i>British Journal of Cancer</i> , 2021, 124, 1524-1532.	2.9	12
321	Screening for BRCA1 and BRCA2 mutations in breast cancer patients from Mexico: the public health perspective. <i>Salud Publica De Mexico</i> , 2009, 51, s191-s196.	0.1	12
322	A protein truncating BRCA1 allele with a low penetrance of breast cancer. <i>Journal of Medical Genetics</i> , 2004, 41, e130-e130.	1.5	11
323	Compliance With Tamoxifen in Women With Breast Cancer and a BRCA1 or BRCA2 Mutation. <i>Journal of Clinical Oncology</i> , 2010, 28, e698-e699.	0.8	11
324	A Prior Diagnosis of Breast Cancer is a Risk Factor for Breast Cancer in Brca1 and Brca2 Carriers. <i>Current Oncology</i> , 2014, 21, 64-68.	0.9	11

#	ARTICLE	IF	CITATIONS
325	CCR 20th Anniversary Commentary: Triple-Negative Breast Cancer in 2015â€”Still in the Ballpark. <i>Clinical Cancer Research</i> , 2015, 21, 3813-3814.	3.2	11
326	Prospective evaluation of body size and breast cancer risk among BRCA1 and BRCA2 mutation carriers. <i>International Journal of Epidemiology</i> , 2018, 47, 987-997.	0.9	11
327	Denosumab and breast cancer risk in postmenopausal women: a population-based cohort study. <i>British Journal of Cancer</i> , 2018, 119, 1421-1427.	2.9	11
328	Use of bone-modifying agents among breast cancer patients with bone metastasis: evidence from oncology practices in the US. <i>Clinical Epidemiology</i> , 2018, Volume 10, 1349-1358.	1.5	11
329	Inherited Variants in BLM and the Risk and Clinical Characteristics of Breast Cancer. <i>Cancers</i> , 2019, 11, 1548.	1.7	11
330	Prevalence of Recurrent Mutations Predisposing to Breast Cancer in Early-Onset Breast Cancer Patients from Poland. <i>Cancers</i> , 2020, 12, 2321.	1.7	11
331	Anthropometric Measures and Risk of Ovarian Cancer Among <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Obesity</i> , 2012, 20, 1288-1292.	1.5	10
332	Age at first full-term birth and breast cancer risk in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 421-426.	1.1	10
333	A generalizable relationship between mortality and time-to-death among breast cancer patients can be explained by tumour dormancy. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 691-703.	1.1	10
334	A clinically structured and partnered approach to genetic testing in Trinidadian women with breast cancer and their families. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 469-477.	1.1	10
335	Retesting of women who are negative for a BRCA1 and BRCA2 mutation using a 20-gene panel. <i>Journal of Medical Genetics</i> , 2020, 57, 380-384.	1.5	10
336	Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation. <i>Gynecologic Oncology</i> , 2020, 159, 820-826.	0.6	10
337	Genes, the environment, and breast cancer. <i>Lancet, The</i> , 2010, 375, 2123-2124.	6.3	9
338	Early-Onset Breast Cancer: What do We Know about the Risk Factors?. <i>Current Oncology</i> , 2011, 18, 204-205.	0.9	9
339	A model for ovarian cancer progression based on inherent resistance. <i>Gynecologic Oncology</i> , 2016, 142, 484-489.	0.6	9
340	The risk of contralateral breast cancer in daughters of women with and without breast cancer. <i>Clinical Genetics</i> , 2016, 89, 332-335.	1.0	9
341	Talc and ovarian cancer. <i>Gynecologic Oncology</i> , 2016, 141, 410-412.	0.6	9
342	Reduced BRCA1 transcript levels in freshly isolated blood leukocytes from BRCA1 mutation carriers is mutation specific. <i>Breast Cancer Research</i> , 2016, 18, 87.	2.2	9

#	ARTICLE	IF	CITATIONS
343	The impacts of neoadjuvant chemotherapy and of cytoreductive surgery on 10-year survival from advanced ovarian cancer. <i>International Journal of Gynecology and Obstetrics</i> , 2021, 153, 417-423.	1.0	9
344	Frequency of Contralateral Prophylactic Mastectomy in Breast Cancer Patients with a Negative BRCA1 and BRCA2 Rapid Genetic Test Result. <i>Annals of Surgical Oncology</i> , 2021, 28, 4967-4973.	0.7	9
345	Genetic variants associated with breast-cancer risk. <i>Lancet Oncology, The</i> , 2011, 12, 415-416.	5.1	8
346	Earlier Age of Onset in BRCA Carriers—Anticipation or Cohort Effect?. <i>Current Oncology</i> , 2011, 18, 257-258.	0.9	8
347	Hospitalizations to Manage Complications of Modern Prostate Cancer Treatment in Older Men. <i>Urology</i> , 2016, 96, 142-147.	0.5	8
348	A high frequency of PALB2 mutations in Jamaican patients with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 591-596.	1.1	8
349	CHEK2 Alleles Predispose to Renal Cancer in Poland. <i>JAMA Oncology</i> , 2019, 5, 576.	3.4	8
350	Breast cancer survival in Nordic BRCA2 mutation carriers—unconventional association with oestrogen receptor status. <i>British Journal of Cancer</i> , 2020, 123, 1608-1615.	2.9	8
351	The Screen Project: Guided Direct-To-Consumer Genetic Testing for Breast Cancer Susceptibility in Canada. <i>Cancers</i> , 2021, 13, 1894.	1.7	8
352	Factors associated with use of hormone therapy after preventive oophorectomy in BRCA mutation carriers. <i>Menopause</i> , 2020, 27, 1396-1402.	0.8	8
353	Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. <i>Gynecologic Oncology</i> , 2022, 164, 514-521.	0.6	8
354	Risk factors for psychological morbidity and the protective role of coping self-efficacy in young women with breast cancer early in diagnosis: a national multicentre cohort study. <i>Breast Cancer Research and Treatment</i> , 2022, 194, 91-102.	1.1	8
355	Ovarian cancer and HRT in the Million Women Study. <i>Lancet, The</i> , 2007, 369, 1667-1668.	6.3	7
356	Clinical implications of genetic testing for <scp>BRCA1</scp> and <scp>BRCA2</scp> mutations in Austria. <i>Clinical Genetics</i> , 2014, 85, 72-75.	1.0	7
357	Age-specific risks of incident, contralateral and ipsilateral breast cancer among 1776 Polish BRCA1 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 769-774.	1.1	7
358	Premenopausal Plasma Osteoprotegerin and Breast Cancer Risk: A Case—Control Analysis Nested within the Nurses' Health Study II. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1264-1270.	1.1	7
359	Rapid Genetic Testing for BRCA1 and BRCA2 Mutations at the Time of Breast Cancer Diagnosis: An Observational Study. <i>Annals of Surgical Oncology</i> , 2021, 28, 2219-2226.	0.7	7
360	Genetic predisposition to male breast cancer in Poland. <i>BMC Cancer</i> , 2021, 21, 975.	1.1	7

#	ARTICLE	IF	CITATIONS
361	Family with Graves disease, multinodular goiter, nonmedullary thyroid carcinoma, and alveolar rhabdomyosarcoma. , 1997, 72, 30-33.		6
362	Hereditary breast carcinoma syndromes. <i>Cancer</i> , 1997, 80, 537-542.	2.0	6
363	Human kallikrein-2 gene and protein expression predicts prostate cancer at repeat biopsy. <i>SpringerPlus</i> , 2014, 3, 295.	1.2	6
364	BRCA1 founder mutations compared to ovarian cancer in Belarus. <i>Familial Cancer</i> , 2014, 13, 445-447.	0.9	6
365	The effect of oral 3,3- $\alpha^2$ -diindolylmethane supplementation on the 2:16 $\pm$ -OHE ratio in BRCA1 mutation carriers. <i>Familial Cancer</i> , 2015, 14, 281-286.	0.9	6
366	Breast Cancer Prevention in the Era of Precision Medicine. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv078-djv078.	3.0	6
367	Does the age of breast cancer diagnosis in first-degree relatives impact on the risk of breast cancer in BRCA1 and BRCA2 mutation carriers?. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 163-169.	1.1	6
368	Impact of a prior diagnosis of DCIS on survival from invasive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 385-393.	1.1	6
369	Survival Differences in Women with and without Autologous Breast Reconstruction after Mastectomy for Breast Cancer. <i>Plastic and Reconstructive Surgery - Global Open</i> , 2017, 5, e1281.	0.3	6
370	Estimating the effect of immortalâ€time bias in urological research: a case example of testosteroneâ€replacement therapy. <i>BJU International</i> , 2017, 120, 584-590.	1.3	6
371	Neoadjuvant chemotherapy for advanced-stage ovarian cancer: Are the ASCO and SGO recommendations warranted?. <i>Gynecologic Oncology</i> , 2017, 144, 238-240.	0.6	6
372	Serum osteoprotegerin levels and mammographic density among high-risk women. <i>Cancer Causes and Control</i> , 2018, 29, 507-517.	0.8	6
373	Short report: Followâ€up of Bahamian women with a <i>BRCA1</i> or <i>BRCA2</i> mutation. <i>Molecular Genetics &amp; Genomic Medicine</i> , 2018, 6, 301-304.	0.6	6
374	Allelic modification of breast cancer risk in women with an NBN mutation. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 427-431.	1.1	6
375	MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc). <i>Lancet Oncology</i> , The, 2019, 20, e465.	5.1	6
376	Blood Arsenic Levels as a Marker of Breast Cancer Risk among BRCA1 Carriers. <i>Cancers</i> , 2021, 13, 3345.	1.7	6
377	Weight Gain and the Risk of Ovarian Cancer in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 2038-2043.	1.1	6
378	An appraisal of genetic testing for prostate cancer susceptibility. <i>Npj Precision Oncology</i> , 2022, 6, .	2.3	6

#	ARTICLE	IF	CITATIONS
379	What options for treatment of hereditary breast cancer?. <i>Lancet, The</i> , 2002, 359, 1451-1452.	6.3	5
380	The Tip of the Iceberg. <i>Current Oncology</i> , 2012, 19, 129-130.	0.9	5
381	Should hysterectomy complement prophylactic salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers?. <i>Gynecologic Oncology</i> , 2014, 134, 219-221.	0.6	5
382	Counterpoint Re: "Mammography Screening" Sticking to the Science. <i>Current Oncology</i> , 2015, 22, 177-177.	0.9	5
383	Which women decide to take tamoxifen?. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 149-155.	1.1	5
384	A comparison of two models for breast cancer mortality for women with ductal carcinoma in situ: an SEER-based analysis. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 587-594.	1.1	5
385	Population-Based Genetic Testing for <i>BRCA1</i> and <i>BRCA2</i> . <i>Journal of Clinical Oncology</i> , 2018, 36, 517-517.	0.8	5
386	Predictors of mammographic density among women with a strong family history of breast cancer. <i>BMC Cancer</i> , 2019, 19, 631.	1.1	5
387	Does preventive oophorectomy increase the risk of depression in BRCA mutation carriers?. <i>Menopause</i> , 2020, 27, 156-161.	0.8	5
388	Breast cancer risk after age 60 among <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 515-523.	1.1	5
389	Plasma RANKL levels are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. <i>Oncotarget</i> , 2019, 10, 2475-2483.	0.8	5
390	Is bilateral radiation an option for BRCA mutation carriers with unilateral breast cancer?. <i>Annals of Translational Medicine</i> , 2019, 7, 165-165.	0.7	5
391	Risk of Second Primary Thyroid Cancer in Women with Breast Cancer. <i>Cancers</i> , 2022, 14, 957.	1.7	5
392	Is There a Future for Ovarian Cancer Screening?. <i>JAMA Internal Medicine</i> , 2018, 178, 611.	2.6	4
393	Prophylactic mastectomy for BRCA mutation carriers after ovarian cancer treatment: is it beneficial?. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 199-200.	1.1	4
394	Assessment of Secondary Sarcomas Among Patients With Cancer of the Abdomen or Pelvis Who Received Combinations of Surgery, Radiation, and Chemotherapy vs Surgery Alone. <i>JAMA Network Open</i> , 2020, 3, e2013929.	2.8	4
395	Long-term outcomes following a diagnosis of ovarian cancer at the time of preventive oophorectomy among <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 825-830.	1.2	4
396	The relationship between the predicted risk of death and psychosocial functioning among women with early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 177-189.	1.1	4

#	ARTICLE	IF	CITATIONS
397	Adjuvant olaparib “ should all patients with breast cancer have genetic testing?. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 607-608.	12.5	4
398	The impact of oophorectomy on survival from breast cancer in patients with CHEK2 mutations. <i>British Journal of Cancer</i> , 2022, 127, 84-91.	2.9	4
399	Analysis ofBRCA1 mutations in a Pakistani family with hereditary breast and ovarian cancer syndrome. , 1998, 78, 386-387.		3
400	Clinical characteristics of breast cancer in patients with an NBS1 mutation. <i>Breast Cancer Research and Treatment</i> , 2013, 141, 471-476.	1.1	3
401	Interest of individuals from BRCA families to participate in research studies focused on male BRCA carriers. <i>Familial Cancer</i> , 2013, 12, 615-619.	0.9	3
402	Breast Cancer and the Environment: What Is Left to Learn?. <i>Current Oncology</i> , 2013, 20, 8-9.	0.9	3
403	RE: Pan-Canadian Study of Mammography Screening and Mortality From Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv094-djv094.	3.0	3
404	Response. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	3
405	Breast Cancer Genetics for Plastic Surgeons. <i>Plastic and Reconstructive Surgery</i> , 2017, 140, 455-460.	0.7	3
406	The impact of an expanded genetic testing program and selective oophorectomy on the incidence of ovarian cancer in West Pomerania. <i>Clinical Genetics</i> , 2017, 91, 322-327.	1.0	3
407	Testing Ashkenazi Jewish Women for Mutations Predisposing to Breast Cancer in Genes Other Than <i>BRCA1</i> and <i>BRCA2</i> . <i>JAMA Oncology</i> , 2018, 4, 1012.	3.4	3
408	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2473.	1.8	3
409	Germline pathogenic variants in BRCA1, BRCA2, PALB2 and RAD51C in breast cancer women from Argentina. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 629-636.	1.1	3
410	Late Recurrences After Estrogen Receptor–Positive Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 301.	3.4	3
411	Preferences for breast cancer prevention among women with a BRCA1 or BRCA2 mutation. <i>Hereditary Cancer in Clinical Practice</i> , 2020, 18, 20.	0.6	3
412	Patient reported experiences following laparoscopic prophylactic bilateral salpingo-oophorectomy or salpingectomy in an ambulatory care hospital. <i>Familial Cancer</i> , 2021, 20, 103-110.	0.9	3
413	Bilateral Oophorectomy and the Risk of Breast Cancer in <i>BRCA1</i> Mutation Carriers: A Reappraisal. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1351-1358.	1.1	3
414	Power of the admixture test to detect genetic heterogeneity. <i>Genetic Epidemiology</i> , 1991, 8, 209-216.	0.6	2



#	ARTICLE	IF	CITATIONS
415	Pathology and genetic testing. <i>Cancer</i> , 1997, 80, 636-648.	2.0	2
416	Ten types of breast cancer?. <i>Lancet, The</i> , 2012, 380, 1212-1213.	6.3	2
417	Prostate cancer in a man with a <i><sc>BRCA2</sc></i> mutation and a personal history of bilateral breast cancer. <i>Clinical Genetics</i> , 2015, 88, 187-189.	1.0	2
418	DCIS and invasive interval breast cancer. <i>Lancet Oncology, The</i> , 2016, 17, e87-e88.	5.1	2
419	Reply to Kopans. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 653-654.	1.1	2
420	Does oophorectomy reduce breast cancer mortality for BRCA mutation carriers after breast cancer?. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 305-306.	1.1	2
421	Clinical Cancer Genetics in a Lower-Middle Income Country: Considerations for Policymaking. <i>Journal of Global Oncology</i> , 2018, 4, 1-3.	0.5	2
422	Reply to "Mutations in RECQL are not associated with breast cancer risk in an Australian population"™. <i>Nature Genetics</i> , 2018, 50, 1348-1349.	9.4	2
423	Gender bias in CIHR Foundation grant awarding. <i>Lancet, The</i> , 2019, 393, 2195.	6.3	2
424	The incidence of fatal breast cancer measures the increased effectiveness of therapy in women participating in mammography screening. <i>Cancer</i> , 2019, 125, 2130-2130.	2.0	2
425	In Response to "Pregnancy After Breast Cancer in Patients With Germline BRCA Mutations". <i>Journal of Clinical Oncology</i> , 2020, 38, 4352-4352.	0.8	2
426	Germline BRCA1 and BRCA2 mutations and the risk of bladder or kidney cancer in Poland. <i>Hereditary Cancer in Clinical Practice</i> , 2022, 20, 13.	0.6	2
427	High Expression of RECQL Protein in ER-Positive Breast Tumours Is Associated With a Better Survival. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
428	Impact of germline mutations in cancer-predisposing genes on long-term survival in patients with epithelial ovarian cancer. <i>British Journal of Cancer</i> , 2022, 127, 879-885.	2.9	2
429	Countercurrents: DCIS or Cancer? Why All the Confusion?. <i>Current Oncology</i> , 2022, 29, 4936-4940.	0.9	2
430	Personalized Medicine: A Personal View. <i>Current Oncology</i> , 2010, 17, 4-5.	0.9	1
431	Are Bilateral Cancers Hereditary? Part II. <i>Current Oncology</i> , 2012, 19, 246-247.	0.9	1
432	The Authors Reply. <i>American Journal of Epidemiology</i> , 2014, 180, 760-761.	1.6	1

#	ARTICLE	IF	CITATIONS
433	Re: Survival Outcomes After Contralateral Prophylactic Mastectomy: A Decision Analysis. Journal of the National Cancer Institute, 2015, 107, djv092-djv092.	3.0	1
434	RE: Germline Mutations in the Kallikrein 6 Region and Predisposition for Aggressive Prostate Cancer. Journal of the National Cancer Institute, 2017, 109, .	3.0	1
435	Reply to Hollingsworth: does breast cancer metastasize in the clinical window between the mammogram and the mass?. Breast Cancer Research and Treatment, 2018, 169, 639-640.	1.1	1
436	Genetic testing for young women with breast cancer. Lancet Oncology, The, 2018, 19, e182.	5.1	1
437	Editorial: Approaches of the treatment of DCIS. Breast, 2018, 37, 161-162.	0.9	1
438	Countercurrents: Is Now the Right Time to Pull the Plug on Mammography?. Current Oncology, 2019, 26, 162-163.	0.9	1
439	Association Between Invasive Lobular Breast Cancer and Mutations in the Mismatch Repair Gene <i>MSH6</i> . JAMA Oncology, 2019, 5, 120.	3.4	1
440	Author response to "response to "personalised medicine and population health: breast and ovarian cancer". Human Genetics, 2019, 138, 291-292.	1.8	1
441	An evaluation of memory and attention in BRCA mutation carriers using an online cognitive assessment tool. Cancer, 2021, 127, 3183-3193.	2.0	1
442	Analysis of BRCA1 mutations in a Pakistani family with hereditary breast and ovarian cancer syndrome. American Journal of Medical Genetics Part A, 1998, 78, 386-387.	2.4	1
443	Letter to the Editor: Radiation for Prior DCIS is a Risk Factor for Death From Invasive Breast Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, xliia.	2.3	1
444	Do BARD1 Mutations Confer an Elevated Risk of Prostate Cancer?. Cancers, 2021, 13, 5464.	1.7	1
445	Influence of Germline <i>BRCA</i> Genotype on the Survival of Patients with Triple-Negative Breast Cancer. Cancer Research Communications, 2021, 1, 140-147.	0.7	1
446	Common Variant in ALDH2 Modifies the Risk of Breast Cancer Among Carriers of the p.K3326* Variant in BRCA2. JCO Precision Oncology, 2022, 6, e2100450.	1.5	1
447	Regarding the Use of Tamoxifen Post-Oophorectomy to Prevent Hereditary Breast Cancer. Hereditary Cancer in Clinical Practice, 2006, 4, 167.	0.6	0
448	Choices for Young Women at Intermediate Risk of Breast Cancer. Current Oncology, 2012, 19, 112-114.	0.9	0
449	The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers. Canadian Urological Association Journal, 2013, 5, 31.	0.3	0
450	Response. Journal of the National Cancer Institute, 2014, 106, dju046-dju046.	3.0	0

#	ARTICLE	IF	CITATIONS
451	Modern approaches to cancer prevention: Universal or personal?. Journal of Cancer Policy, 2014, 2, 93-96.	0.6	0
452	Prevalence of PALB2 mutations in the Creighton University Breast Cancer Family Registry. Breast Cancer Research and Treatment, 2015, 150, 637-641.	1.1	0
453	Response to "Comments on 'The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study'"™™. British Journal of Cancer, 2016, 115, e4-e4.	2.9	0
454	Common genetic susceptibility to DCIS and invasive ductal carcinoma. Breast Cancer Research, 2016, 18, 60.	2.2	0
455	Response to Evans et al.. Clinical Genetics, 2016, 89, 400-400.	1.0	0
456	Mutation Frequencies in Patients With Early-Onset Colorectal Cancer. JAMA Oncology, 2017, 3, 1586.	3.4	0
457	Comparing Adjuvant vs Early-Salvage Radiotherapy After Radical Prostatectomy. JAMA Oncology, 2018, 4, 1620.	3.4	0
458	Cancer Risk Estimates for Study of Multiple-Gene Testing After Diagnosis of Breast Cancer. JAMA Oncology, 2018, 4, 1787.	3.4	0
459	Genetic testing for breast cancer in the Hispanic community. Cancer, 2019, 125, 2728-2729.	2.0	0
460	Outcomes of breast reconstruction following prophylactic bilateral mastectomy. Breast Journal, 2020, 26, 1637-1638.	0.4	0
461	Mammography screening for breast cancer—the UK Age trial. Lancet Oncology, The, 2020, 21, e508.	5.1	0
462	Countercurrents: The Last Trial. Current Oncology, 2021, 28, 275-277.	0.9	0
463	Abstract 857: Evaluating the relationship between arsenic exposure and cancer risk in Canada. , 2021, , .		0
464	On the road with Henry Lynch. Hereditary Cancer in Clinical Practice, 2020, 18, 2.	0.6	0
465	The risks of breast and ovarian cancer associated with the Ashkenazi Jewish founder allele <sc><i>BRCA2</i> 6174delT</sc>. Clinical Genetics, 2022, 101, 317-323.	1.0	0
466	Abstract 5942: Vitamin D, calcium supplement use and the risk of breast cancer in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers: A case-control study. Cancer Research, 2022, 82, 5942-5942.	0.4	0